Y-mAbs Therapeutics, Inc. (YMAB)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Novel Antibody-based Therapeutic Products	85.19M

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
United States	65.98M
Eastern Asia	7.46M
Latin America	4.72M
Western Asia	4.05M
Western Europe	2.09M
Other Regions	890.00K

Data Source: Finnhub Last updated: Jun 30, 2025

Financial data is provided by Finnhub and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jan 1, 2000

Data Sources Report a data error